US · BRKR
Bruker Corporation
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Billerica, MA 01821
- Website
- bruker.com
Price · as of 2025-12-31
$36.79
Market cap 6.09B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $39.25 | +6.69% |
| Intrinsic Value(DCF) | $15.92 | -56.73% |
| Graham-Dodd Method(GD) | $13.76 | -62.6% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $15.02 | $39.69 | $67.18 | $5.96 | $18.74 |
| 2012 | $17.82 | $38.43 | $24.69 | $5.89 | $7.55 |
| 2013 | $22.90 | $41.83 | $0.51 | $6.75 | $5.11 |
| 2014 | $18.16 | $39.22 | $1.14 | $5.53 | $2.23 |
| 2015 | $26.96 | $41.21 | $1.45 | $6.60 | $0.00 |
| 2016 | $23.04 | $38.95 | $1.62 | $5.85 | $7.01 |
| 2017 | $30.04 | $41.57 | $0.62 | $3.64 | $8.61 |
| 2018 | $36.68 | $44.46 | $1.10 | $7.37 | $17.50 |
| 2019 | $43.80 | $52.22 | $3.31 | $7.89 | $21.75 |
| 2020 | $60.45 | $55.98 | $1.07 | $6.92 | $4.23 |
| 2021 | $62.26 | $66.73 | $106.43 | $11.58 | $52.70 |
| 2022 | $71.37 | $65.69 | $10.07 | $11.39 | $25.01 |
| 2023 | $90.49 | $72.53 | $111.08 | $17.00 | $71.73 |
| 2024 | $48.17 | $44.52 | $50.99 | $2.59 | $16.05 |
| 2025 | $39.81 | $39.25 | $0.00 | $13.76 | $0.00 |
AI valuation
Our deep-learning model estimates Bruker Corporation's (BRKR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $39.25
- Current price
- $36.79
- AI upside
- +6.69%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$15.92
-56.73% upside
Graham-Dodd
$13.76
-62.6% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BRKR | Bruker Corporation | $36.79 | 6.09B | +7% | -57% | -63% | — | 206.96 | 2.44 | 1.76 | 17.43 | — | -7.46 | 45.61% | 6.30% | -0.25% | 1.37% | 2.20% | 0.48% | 0.76 | 4.69 | 1.73 | 0.66 | 3.59 | -11974.00% | 208.00% | -6816.00% | 0.72% | 0.10 | 1.10% | 0.38% | 78.10% | 8.68% | 35.15 | 175.83 | 2.22 | 1.82 |
| BTSG | BrightSpring Health Servi… | $41.43 | 7.47B | +60% | +485% | -97% | -50% | 44.17 | 4.49 | 0.65 | 24.32 | — | -6.86 | 11.76% | 3.06% | 1.48% | 10.82% | 6.59% | 3.09% | 1.52 | 2.51 | 1.57 | 0.58 | 5.99 | -102949.00% | 1459.00% | -79075.00% | 4.69% | 0.27 | 8.65% | 0.00% | 0.00% | 1.57% | 28.26 | 28.32 | 0.87 | 3.51 |
| CHE | Chemed Corporation | $410.01 | 5.97B | -25% | -56% | -80% | -46% | 22.87 | 6.19 | 2.40 | 14.53 | — | 26.42 | 29.97% | 13.37% | 10.48% | 25.28% | 23.68% | 16.54% | 0.15 | 193.28 | 1.05 | 0.90 | 0.16 | -739.00% | 406.00% | -1155.00% | 5.36% | 1.35 | 30.56% | 0.52% | 11.90% | 7.63% | 18.14 | 18.85 | 2.43 | 9.79 |
| CRSP | CRISPR Therapeutics AG | $60.14 | 5.77B | -40% | -46% | — | +738% | -9.40 | 2.84 | 1556.91 | -7.08 | -19.15 | 2.84 | -6537.01% | -16191.40% | -16569.77% | -30.18% | -191.73% | -25.81% | 0.21 | — | 13.32 | 13.25 | -0.07 | 4908.00% | -8997.00% | 13911.00% | -6.33% | -2.31 | -116.70% | 0.00% | 0.00% | 0.00% | -6.83 | -11.23 | 1106.51 | 8.49 |
| GKOS | Glaukos Corporation | $120.40 | 6.99B | -42% | +3% | — | — | -51.83 | 10.56 | 13.65 | -45.16 | -281.48 | 15.48 | 55.72% | -39.33% | -36.99% | -18.78% | -36.24% | -14.31% | 0.21 | -43.06 | 4.69 | 3.82 | -0.32 | 1841.00% | 3233.00% | -2013.00% | -0.78% | -0.46 | -10.09% | 0.00% | 0.00% | 0.00% | -34.01 | -125.68 | 13.38 | 16.38 |
| IRTC | iRhythm Technologies, Inc… | $133.75 | 4.32B | -14% | +116% | — | — | -92.28 | 26.92 | 5.50 | -1074.06 | — | 27.07 | 70.57% | -4.93% | -5.96% | -36.57% | -12.43% | -4.57% | 4.79 | -2.80 | 4.63 | 4.34 | -124.89 | -6171.00% | 2624.00% | -21299.00% | 0.84% | 0.53 | 11.65% | 0.00% | 0.00% | 0.00% | -115.69 | 123.36 | 5.70 | 3.00 |
| KRYS | Krystal Biotech, Inc. | $275.64 | 8.06B | -24% | -34% | -72% | +4% | 36.57 | 6.14 | 19.25 | 39.75 | 28.57 | 6.14 | 92.61% | 41.45% | 52.64% | 18.91% | 42.60% | 17.14% | 0.01 | — | 9.95 | 9.28 | -2.90 | 12800.00% | 3394.00% | 5851.00% | 2.52% | 1.95 | 49.90% | 0.00% | 0.00% | 1.99% | 41.37 | 35.32 | 17.15 | 40.89 |
| MMSI | Merit Medical Systems, In… | $77.18 | 4.58B | +4% | -60% | -62% | -45% | 35.22 | 2.86 | 2.99 | 14.98 | 715.00 | 8.38 | 48.70% | 12.19% | 8.48% | 8.67% | 7.25% | 5.03% | 0.57 | 6.98 | 4.34 | 2.80 | 1.35 | 493.00% | 1175.00% | 1800.00% | 4.77% | 1.24 | 11.26% | 0.00% | 0.00% | 0.00% | 26.93 | 23.07 | 3.28 | 4.04 |
| TFX | Teleflex Incorporated | $122.06 | 5.39B | -20% | -55% | — | +315% | -6.06 | 1.76 | 2.75 | 17.49 | — | -7.79 | 56.24% | 2.94% | -45.45% | -24.47% | 1.35% | -12.90% | 0.06 | 0.58 | 2.54 | 0.95 | -0.64 | -146824.00% | -3461.00% | -9972.00% | 0.03% | 0.13 | 0.03% | 1.10% | -6.70% | 36.82% | 90.40 | 3659.08 | 2.66 | 2.01 |
| TGTX | TG Therapeutics, Inc. | $30.09 | 4.78B | +200% | +4,085% | -34% | +845% | 9.49 | 6.55 | 6.88 | 33.25 | 0.54 | 6.55 | 83.62% | 20.01% | 72.56% | 102.75% | 36.31% | 54.50% | 0.01 | 4.61 | 4.10 | 2.91 | -0.58 | 174667.00% | 8732.00% | -3840.00% | -0.59% | -0.16 | -7.36% | 0.00% | 0.00% | 5.57% | 33.32 | -164.45 | 6.67 | 6.21 |
| TMDX | TransMedics Group, Inc. | $145.26 | 4.96B | -12% | +2,727% | -71% | +68% | 26.26 | 10.56 | 8.25 | 33.53 | 6.87 | 10.87 | 59.92% | 17.93% | 31.43% | 54.24% | 25.12% | 20.33% | 0.99 | 7.88 | 7.14 | 6.41 | -0.13 | 38218.00% | 3713.00% | -26504.00% | 2.67% | 2.16 | 30.90% | 0.00% | 0.00% | 4.01% | 45.85 | 37.27 | 8.22 | 6.19 |
About Bruker Corporation
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
- CEO
- Frank H. Laukien
- Employees
- 11.4K
- Beta
- 1.18
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($15.92 ÷ $36.79) − 1 = -56.73% (DCF, example).